Fundraising FoxSectoral Asset Management
Institutional investorMontreal · Series B–Late Stage · 9 people tracked
Find your way into Sectoral Asset Management
Each arrow is one introduction. Sign up to fill in the first one.
Ask Xavier Fernandez to introduce you to Oern R. Stuge
You →Xavier · together at Carthera →Oern
Ask Jamie Chen to introduce you to Gabriel Douville
You →Jamie · together at Paladin Labs →Gabriel
Ask Sam Okafor to introduce you to François Beaubien
You →Sam · together at Pipeline Therapeutics →François
- Marc-André Marcotte214 people can intro you
- Michael Sjöström22 people can intro you
- Howard Riback4 people can intro you
Sign up to find every way you can get introduced to Sectoral Asset Management
- Your email: who you already know at Sectoral Asset Management, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sectoral Asset Management team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Sectoral's venture arm invests in innovative healthcare companies through its late-stage NEMO family of funds, active since 2008 across North America and Europe. A newer fund, Fonds Medtech Ventures (2023), targets Canadian medtech companies. The team supports portfolio companies with capital and operational expertise to help bring new therapeutics and medical devices to patients worldwide. Its philosophy holds that strong financial returns can align with lasting societal benefits through improved health and well-being.
Source: firm website, verified Sep 29, 2026.
Team · 9 people
from curated & public directoriesWhat they invest in
from 13 of 14 portfolio companiesHealthtech ×10Medical Devices ×9Biotech ×7Hardware ×4Digital Health ×3Deep Tech ×1Wellness & Fitness ×1
HQs:United States×11
Investments · 14 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 12024 · 22023 · 22022 · 12021 · 12020 · 12018 · 212 dated
Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients.
BiotechDigital HealthHealthtechCambridge, US
Lawrence G. Miller(Executive Officer, Director)inDennis Molnar(Executive Officer)inBarry Wohl(Chief Business Officer)inKetan Mehta(Head of Product and Engineering, Connected Wearables)Ron Farquhar(Director)Gerald Chan(Director)
Co-investorsAlpha Wave GlobalHEALTHCARE ROYALTY PARTNERSMorningside Group
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestRA CapitalWellington ManagementAlexandriaCity Hill Ventures+4 more
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureSamsara BioCapitalCasdin CapitalFranklin TempletonJJDC+1 more
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersLSP (Life Sciences Partners)+5 more
BiotechSan Leandro, US
Steve Abella(Chief Medical Officer)inGraeme Currie(Chief Operating Officer)inStephen W. Lau(President, Chief Executive Officer, and Treasurer)inKenneth Schwartz(Executive Officer)inEric Yuen(Executive Officer)inMarten Steen(Director)in
Co-investorsHealthCapInkefSofinnova VenturesYsios Capital
CurvaFix develops the CurvaFix Low Profile intramedullary nailing system, curved implants for surgical stabilization of pelvic fractures.
HardwareHealthtechMedical DevicesBellevue, US
Jeffrey Poole(Executive Officer)Mark Foster(Executive Officer, Director)inSteven Dimmer(Executive Officer, Director, Promoter)Dong-Gun Kim(Director)
BoardEric Fritz(Director)inJack Tanaka(Director)in
Co-investorsAlliance of AngelsArieal Southeast Angel PartnersRockies Venture ClubSPRINGROCK VENTURESSwan Venture FundKeiretsu Capital+2 more
LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.
BiotechHealthtechMedical DevicesSan Diego, US
James McCollum(Co-founder, Board Member)Eef SchimmelpenninkinEvert Schimmelpennink(President and CEO)
Co-investorsAlpha Wave GlobalRA CapitalRaptor GroupRTW Investments L.P.Versant Ventures
Magnolia Medical develops diagnostic devices to reduce blood culture contamination and false-positive sepsis test results for hospitals and healthcare systems.
HardwareHealthtechMedical DevicesSeattle, US
Gregory J Bullington(Executive Officer, Director)Richard Patton(Co-founder)
BoardPaul Meister(Director)
Co-investorsEvidity Health CapitalLauder PartnersMarram VenturesRhapsody Venture PartnersVivo CapitalHealthQuest Capital+3 more
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)in
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+6 more
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)
BoardChau Khuong(Director)inAllan May(Director)Mudit Jain(Director)inTracy Pappas(Director)in
Co-investorsAngelini VenturesBlue Venture FundsJoyance PartnersOrbiMedTreo Ventures, LlcZühlke Ventures+2 more
Phagenesis develops targeted pharyngeal electrical stimulation technology to treat neurogenic dysphagia by restoring neural pathways for safe swallowing.
Deep TechDigital HealthHealthtechMedical Devices
Co-investorsAphelion CapitalInnvotec Ltd.Northern GritstoneEQT Life Sciences
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.
BiotechHardwareHealthtechMedical DevicesSan Mateo, US
Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)inDr. Joey English(Chief Medical Officer)Tony Chou(Executive Officer, Director)in
BoardJack Lasersohn(Director)inTamir Meiri(Director)
Co-investorsNovo HoldingsThe Vertical GroupNorwest Venture PartnersRunway Growth CapitalUS Venture PartnersSofinnova Ventures+1 more
Shockwave Medical develops intravascular lithotripsy (IVL) catheter systems used to treat calcified cardiovascular disease, marketed to interventional cardiologists and vascular specialists.
HardwareHealthtechMedical DevicesFremont, US
Daniel Hawkins(Executive Officer, Director)inTodd J. Brinton(Director)inIsaac(President)
BoardJay Watkins(Director)inAntoine Papiernik(Director)inFrederic H. Moll(Director)
Co-investorsSofinnova PartnersSonder CapitalVenrock
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 3
3 IPOsApnimedNASDAQ: APMDBoundless BioNASDAQ: BOLDContineum TherapeuticsNASDAQ: CTNM
Portfolio news
latest coverage across their companiesApnimed · forbes.com · Jul 31, 2026
Noctrix Health · finsmes.com · Sep 2, 2025
Neuros Medical · finsmes.com · Jul 9, 2025
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Contineum Therapeutics | 4.1% | $16.00 | Apr 2024 | $15.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Sectoral Asset Management made?
- Sectoral Asset Management has 14 tracked investments, 3 of which have exited, including 3 dated in the last 24 months.
- What stage does Sectoral Asset Management invest at?
- Sectoral Asset Management invests at the Series B, Late Stage stages.
- What sectors does Sectoral Asset Management focus on?
- Sectoral Asset Management focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Sectoral Asset Management located?
- Sectoral Asset Management is headquartered in Montreal, CA.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.